Medical Marijuana, Inc. Successfully Defeats Project CBD’s Anti-SLAPP Motion and Motion to Reconsider in $100 Million False Claims Lawsuit
MJNA Moves Forward With Prosecuting Libel Claims Made Against the Company and Its Brands, Case Now in Discovery Phase
“The Trial Court has now twice ruled that the case can proceed against Project CBD, Martin Lee and Aaron Cantu on the causes of action for Libel and False Light,” says Dr. Stuart Titus, the CEO of Medical Marijuana, Inc. “While it’s unfortunate that it came to this, Medical Marijuana, Inc. intends to use all available resources to aggressively prosecute this case and proceed to trial.”
In filing the Anti-SLAPP motion, Project CBD had attempted to have Medical Marijuana, Inc.’s $100 million lawsuit dismissed on the grounds that it violated Project CBD’s right to free speech.
Public court documents show that Project CBD had argued in their defense that Medical Marijuana, Inc. was the equivalent of a public figure and the Company was using the $100 million lawsuit to censor public discourse.
In his recent ruling, the California Superior Court judge disagreed with Project CBD’s argument and denied the Anti-SLAPP motion. In the ruling, the judge also found that Medical Marijuana, Inc. has grounds to proceed with their lawsuit against Project CBD on the grounds of Libel and False Light.
“Unfortunately, integrity can take a great deal of time to prove,” Titus says. “However, Medical Marijuana, Inc. is determined to see this fight through to the end and vindicate ourselves to the world.”
For details on Medical Marijuana, Inc.’s portfolio and investment companies, visitwww.medicalmarijuanainc.com.
About Medical Marijuana, Inc.
Our mission is to be the premier hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at:www.MedicalMarijuanaInc.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of hemp-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
For further information, please contact: Public Relations contact: Andrew Hard Spokesperson CMW Media P. 858-380-5478 andrew.hard@cmwmedia.com Corporate contact: Medical Marijuana, Inc. Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc Investor Relations: GH Investment Advisors 550 West "C" Street, Ste. 2040 San Diego, CA 92101 Nick Massalas Office: (858) 264-6500 Toll Free: (877) 964-6463 info@ghinvestmentadvisors.com
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
